HistoSonics key facts
as of Oct 2026- Developer of a non-invasive and robotically assisted ultrasound therapy device designed for precise tissue destruction.
- HistoSonics is valued at approximately $610.0M as of Oct 2026, set at its later-stage round, Aug 2024; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $250.0M across 3 recorded rounds; the latest was Later Stage VC ($102.0M) in Jul 2024.
- Notable investors include Founders Fund, K5 Global, Alpha Wave Global, Wellington Management, Johnson & Johnson JJDC — 16 tracked in total.
- HistoSonics has filed 4 Form Ds with the SEC since 2020, most recently Aug 2024 ($102.0M sold to 39 investors).
- Status: Privately Held (backing).
Valued at $610.0M at its later-stage round, Aug 2024. Nothing has traded since.
- ·The complete investor list: 16 names
- ·Watch HistoSonics: the Monday email on marks, rounds and moves
HistoSonics funding rounds
3 roundsWho backs HistoSonics
16+HistoSonics valuation
HistoSonics was valued at $610 million at its later-stage round in Aug 2024. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has HistoSonics raised?
HistoSonics has raised $250 million across 3 recorded rounds since 2020. The largest was an $85 million debt round in Dec 2022; the most recent was a $102 million later-stage round in Jul 2024.
HistoSonics has filed 4 Form Ds with the SEC since 2020, most recently in Aug 2024 ($102 million sold to 39 investors).
HistoSonics investors
16 investors are on record for HistoSonics, including Founders Fund, K5 Global, Alpha Wave Global and Wellington Management. By type, the record holds 4 venture capital firms, 2 growth equity firms and 1 family office. The later-stage round in Jul 2024 drew 39 investors.
About HistoSonics
Developer of a non-invasive and robotically assisted ultrasound therapy device designed for precise tissue destruction. The company's device utilizes focused sound energy to mechanically break down targeted tissue at a sub-cellular level, offering continuous visualization, real-time physician control, and personalized treatment adjustments. operates without incisions or needles, integrating advanced imaging and adaptive energy delivery, enabling healthcare providers to treat unresectable tumors with enhanced accuracy, reduced procedural complexity, and minimized patient recovery time.
- Sector
- Healthcare
- HQ
- Plymouth, MN, United States
- Founded
- 2009
- Employees
- 283
- Website
- histosonics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.